ADELAIDE, Australia – Australian biopharmaceutical companies engaged in drug development shouldn't waste their time trying to build a flagship company in Australia, said Race Oncology Ltd. CEO Peter Molloy. Rather, they should focus on partnering with big pharma as early as possible, he told attendees of the Ausbiotech conference.
ADELAIDE, Australia – Australian biopharmaceutical companies engaged in drug development shouldn't waste their time trying to build a flagship company in Australia, said Race Oncology Ltd. CEO Peter Molloy. Rather, they should focus on partnering with big pharma as early as possible, he told the Ausbiotech conference.
PERTH, Australia – Novartis AG's recent tender offer to acquire radiopharmaceuticals specialist Advanced Accelerator Applications SA (AAA) for $3.9 billion could bode well for Aussie radiopharma company Telix Pharmaceuticals Ltd., which announced its IPO to raise A$50 million (US$38.4 million) on the Australian Securities Exchange.
PERTH, Australia – Companies in the regenerative medicine space have long been pushing the Therapeutic Goods Administration (TGA) to regulate autologous cell and tissue products in Australia, and they strongly support the agency's moves toward stronger regulation.
PERTH, Australia – Companies in the regenerative medicine space have long been pushing the Therapeutic Goods Administration (TGA) to regulate autologous cell and tissue products in Australia, and they strongly support the agency’s moves toward stronger regulation.
PERTH, Australia – Novartis AG's recent tender offer to acquire radiopharmaceuticals specialist Advanced Accelerator Applications SA (AAA) for $3.9 billion could bode well for Aussie radiopharma company Telix Pharmaceuticals Ltd., which announced its IPO to raise A$50 million (US$38.4 million) on the Australian Securities Exchange.
ADELAIDE, Australia – Australia's life sciences sector is expected to bring in almost A$3 trillion (US$2.2 trillion) by 2025. The government is pumping funds into the sector and working with industry to update regulations and building needed translational infrastructure to attract global attention.
